Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Non-Oral Extravascular Drug Absorption Routes01:15

Non-Oral Extravascular Drug Absorption Routes

214
Non-oral extravascular routes, which encompass sublingual, buccal, topical, intramuscular, and inhalation methods, primarily utilize passive diffusion to transport drugs into the systemic circulation. The absorption rates and effectiveness of these routes depend on the drug's physicochemical properties, as well as the patient's anatomical and pathophysiological state.
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...
214
Drug Absorption: Overview01:17

Drug Absorption: Overview

580
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
580
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

422
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
422
Factors Influencing Drug Absorption: Presystemic Elimination01:24

Factors Influencing Drug Absorption: Presystemic Elimination

212
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
212
Methods for Studying Drug Absorption: In situ01:09

Methods for Studying Drug Absorption: In situ

227
In situ experiments, such as the Doluisio method and Single-Pass Perfusion technique, provide critical insights into drug uptake by simulating in vivo conditions for drug absorption.
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
227
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

451
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
451

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival differences and artemisinin resistance in severe malaria among HIV coinfected patients: data from Mozambique.

medRxiv : the preprint server for health sciences·2026
Same author

MS/MS Mass Spectrometry Filtering Tree for Bile Acid Isomer Annotation.

bioRxiv : the preprint server for biology·2026
Same author

Community Curation of Microbial Metabolites Enables Biological Insights of Metabolomics Data.

bioRxiv : the preprint server for biology·2026
Same author

Transforming the Health Research Workforce in Mozambique: Achievements of the Mozambique Institute for Health Education and Research (MIHER) over a 13‑Year Journey.

Annals of global health·2024
Same author

The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Shaping the Future of Infectious Diseases: The Journey to Promote Value, Opportunity, and Positive Messaging.

Open forum infectious diseases·2024

Related Experiment Video

Updated: Jun 26, 2025

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

8.6K

User Experience of Persons Using Ingestible Sensor-Enabled Pre-Exposure Prophylaxis to Prevent HIV Infection:

Sara Browne1,2, Anya Umlauf3, David J Moore3

  • 1Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, United States.

JMIR Mhealth and Uhealth
|May 9, 2024
PubMed
Summary

User experience with ingestible sensors (ISs) for HIV pre-exposure prophylaxis (PrEP) was positive. Higher self-efficacy correlated with better UX, while depressive symptoms and poor sleep impacted perceived utility and overall experience.

Keywords:
HIVHIV preventionSTDSTIUXadherencecompliancedrugdrugsingestible sensormedicationmedication adherencemedicationsoralpharmaceuticpharmaceuticalpharmaceuticalspharmaceuticspharmaciespharmacologypharmacotherapypharmacypreventionprophylaxissensorsensorssexual transmissionsexually transmittedsexually transmitted diseasesexually transmitted infectionuser experience

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.4K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K

Related Experiment Videos

Last Updated: Jun 26, 2025

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

8.6K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.4K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K

Area of Science:

  • Digital health
  • HIV prevention
  • Medication adherence

Background:

  • Digital health technology success hinges on user acceptance.
  • User experience (UX) is crucial for evaluating new health technologies.

Purpose of the Study:

  • Evaluate the user experience (UX) of a digital health system with ingestible sensors (ISs) for oral pre-exposure prophylaxis (PrEP) adherence.
  • Analyze baseline participant characteristics associated with positive or negative UX.

Main Methods:

  • Prospective study of HIV-negative adults using IS-enabled PrEP (IS-Truvada).
  • Collected baseline data: demographics, toxicology, sleep quality, self-efficacy, perceived risk of HIV, and depressive symptoms.
  • Administered a 27-question UX questionnaire assessing overall experience, ease of use, future use intention, and perceived utility.

Main Results:

  • Over 75% of participants reported favorable overall UX, ease of use, and perceived utility.
  • Higher self-efficacy was significantly associated with better total UX scores and all subscores.
  • Increased depressive symptoms correlated with higher perceived utility; poor sleep was linked to worse overall experience.

Conclusions:

  • The digital health system with ingestible sensors for PrEP demonstrated positive user experience.
  • Self-efficacy, depressive symptoms, and sleep quality are key factors influencing the UX of digital health adherence tools.